Renpho

Life Biosciences in-licenses IP from new studies

Latest articles

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...

Most read

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics. US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...
Apollo Neuro

Editor's picks

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...
Renpho

Studies “open a new frontier in biotechnology and medicine,” says Life Biosciences CEO.

Intellectual property generated by the scientific findings behind two recent publications in Nature, has been in-licensed by Boston-based longevity powerhouse Life Biosciences, with the goal of developing new therapies for age-related conditions.

The publications, based on research conducted in animal models, describe new mechanisms for reversing age-related disease, showing that therapies targeting the biology of aging have the potential to not only slow the progression but also to reverse aging-related disease.

Longevity.Technology: Groundbreaking longevity research is always fascinating in itself, but it’s even more exciting when that research becomes part of a commercial venture. Life Biosciences is one of key players in commercialising the extension of healthy human lifespan, so we’ll be watching with interest to see what happens with this IP in due course.

In a statement, Life Bioscience’s CEO Mehmood Khan said, “These two studies open a new frontier in biotechnology and medicine. They pave the way for the development of groundbreaking treatments to restore the function of aging organ systems and thereby allow people to live healthier longer.”

Mehmood Khan
Life Biosciences CEO Mehmood Khan

One of the studies was led by Life Biosciences co-founder David Sinclair and showed that neurons in the eye can be reset to a youthful state in which their ability to regenerate is switched back on. Researchers rejuvenated damaged or aged cells in the eye with a gene therapy that induced expression of three of the Yamanaka factor proteins. This gene therapy allowed nerves in the eye to regrow after injury and safely restored vision, both in old mice and in a mouse model of glaucoma.

Life Biosciences subsidiary, Iduna Therapeutics, has licensed IP from Harvard University covering a patented gene therapy system for the expression of specific factors known to induce pluripotency and rejuvenation.

“The study shows for the first time that it may be possible to wind the clock back in complex tissues to restore youthful biological functions such as vision,” said Sinclair. “It is promising research in terms of how we address aging-related diseases, including diseases such as glaucoma, which affect many patients later in life.”

Ana Maria Cuervo
Life Biosciences founder scientist Ana Maria Cuervo

The second article reports on studies led by Life Biosciences founder scientist Ana Maria Cuervo, which found that the diminished ability of old mouse and human hematopoietic stem cells (HSCs) to produce new blood cells is correlated with a decline in a process called chaperone-mediated autophagy (CMA).

CMA breaks down unwanted proteins in cells and recycles them into nutrients. When CMA was activated in the hematopoietic stem cells of geriatric mice, either genetically or by treatment with a small molecule, the old stem cells regained the capacity of young stem cells to generate new blood cells. The findings indicate that therapies that activate CMA have the potential to restore the function of aging hematopoietic stem cells and improve immune function.

Life Bioscience’s lab. Image: Matt Kalinowski Photography/Life Biosciences

Life Biosciences has in-licensed the IP related to targeting of CMA from Albert Einstein College of Medicine.

“By activating chaperone-mediated autophagy, we are able to restore the functionality of hematopoietic stem cells in both old mice and older humans, which has very important therapeutic implications,” said Cuervo. “We are looking forward to further investigating how we can put chaperone-mediated autophagy to use in restoring the vitality of aging cells in older people.”

Images courtesy of Matt Kalinowski Photography/Life Biosciences

Comment on this article

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Renpho

Most popular

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics. US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...

AI-enabled doctors will specialise in longevity medicine

We explore what this paper will mean for longevity, with exclusive insights from the authors. In January 2021 a paper entitled Artificial Intelligence in Longevity Medicine...
Apollo Neuro

Related articles

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...

Gene-editing tool can programme cuts over time

New process uses special molecules called 'proGuides' to improve CRISPR gene editing. Researchers from the University of Illinois Chicago have discovered a new gene-editing technique...

A new link in longevity therapeutics

A key review sums up evidence linking DNA damage to senescence through cytoplasmic chromatin fragments, opening a new avenue for longevity therapeutics. Cellular senescence is...

Spermidine may halt aging by preserving telomere length

Researchers show that the natural autophagy-inducing compound spermidine may protect mice from age-related disorders by preventing telomere erosion. Aging is a natural process characterised by...
TruNigen pf